WALTHAM, Mass., April 1, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that it has been added to the Russell 3000® Index, which measures the performance of the 3,000 largest publicly-traded U.S. companies based on total market capitalization. The Russell 3000 Index is constructed to provide a comprehensive barometer of the broad market and is reconstituted annually to capture new and growing companies.
"Following our initial public offering on February 4, 2011, we are very pleased to be added to the Russell 3000 Index," said Pieter Muntendam, M.D., president and chief executive officer of BG Medicine. "Our inclusion in this index provides additional visibility for BG Medicine in the investment community as many investors rely on the Russell indices as part of their investment strategy."
About BG Medicine
BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine recently launched the galectin-3 test for use in patients with heart failure. The galectin-3 test is the first novel blood test for cardiac disease cleared by the FDA in five years. For additional information about BG Medicine and galectin-3 testing, please visit and .
The BG Medicine Inc. logo is available at
CONTACT: Michael W. Rogers EVP & Chief Financial Officer (781) 890-1199
